GSA Capital Partners’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $814K | Sell |
897,611
-39,281
| -4% | -$35.6K | 0.06% | 589 |
|
|
2025
Q1 | $423K | Buy |
936,892
+528,055
| +129% | +$238K | 0.04% | 911 |
|
|
2024
Q4 | $205K | Buy |
408,837
+315,805
| +339% | +$158K | 0.02% | 1403 |
|
|
2024
Q3 | $84K | Buy |
+93,032
| New | +$84K | 0.01% | 1503 |
|
|
2023
Q3 | – | Sell |
-13,196
| Closed | -$19K | – | 1724 |
|
|
2023
Q2 | $19K | Buy |
+13,196
| New | +$19K | ﹤0.01% | 1444 |
|
|
2022
Q4 | – | Sell |
-48,628
| Closed | -$55K | – | 1694 |
|
|
2022
Q3 | $55K | Sell |
48,628
-69,680
| -59% | -$78.8K | 0.01% | 1414 |
|
|
2022
Q2 | $187K | Buy |
118,308
+45,802
| +63% | +$72.4K | 0.03% | 1088 |
|
|
2022
Q1 | $112K | Buy |
+72,506
| New | +$112K | 0.02% | 1275 |
|
|
2021
Q2 | – | Sell |
-80,000
| Closed | -$188K | – | 1475 |
|
|
2021
Q1 | $188K | Buy |
+80,000
| New | +$188K | 0.03% | 925 |
|
|
2020
Q3 | – | Sell |
-15,191
| Closed | -$13K | – | 1323 |
|
|
2020
Q2 | $13K | Buy |
+15,191
| New | +$13K | 0.01% | 566 |
|
|
2018
Q1 | – | Sell |
-190,671
| Closed | -$359K | – | 1725 |
|
|
2017
Q4 | $359K | Sell |
190,671
-9,144
| -5% | -$17.2K | 0.02% | 1122 |
|
|
2017
Q3 | $496K | Buy |
199,815
+110,661
| +124% | +$275K | 0.03% | 972 |
|
|
2017
Q2 | $246K | Buy |
+89,154
| New | +$246K | 0.02% | 1401 |
|